Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06482112 · ClinicalTrials.gov registry record · Phase 2
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
A Phase 2 study of Non-alcoholic Fatty Liver Disease and Liver Disease, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT06482112: Completed Phase 2 study of Non-alcoholic Fatty Liver Disease and Liver Disease, sponsored by Merck Sharp & Dohme.
NCT06482112 is a Phase 2 study of Non-alcoholic Fatty Liver Disease and Liver Disease that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 124 participants, below the 175-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06482112, a Phase 2 study of Non-alcoholic Fatty Liver Disease and Liver Disease, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.
Primary Outcome
Liver fat content (LFC) was measured with liver images taken by magnetic resonance imaging estimated proton density fat fraction (MRI-PDFF) and analyzed by blinded independent central review (BICR). Relative Reduction from Baseline to Week 28 = (Baseline - Week 28) / Baseline x 100%. Least Squares (LS) Mean relative reduction from baseline in LFC is presented.
Conditions Studied
Interventions
- DRUG Efinopegdutide
Study Locations (20)
California
- Om Research LLC ( Site 0207) - Camarillo
- Gastroenterology and Liver Institute ( Site 0263) - Escondido
- Velocity Clinical Research, Gardena ( Site 0235) - Gardena
- Velocity Clinical Research, Huntington Park ( Site 0210) - Huntington Park
- California Liver Research Institute ( Site 0216) - Pasadena
- Acclaim Clinical Research ( Site 0241) - San Diego
- Velocity Clinical Research, Santa Ana ( Site 0250) - Santa Ana
- Velocity Clinical Research, Panorama City ( Site 0228) - Van Nuys
Florida
- Excel Medical Clinical Trials ( Site 0268) - Boca Raton
- AGA Clinical Trials ( Site 0274) - Hialeah
- Neoclinical Research ( Site 0275) - Hialeah
- Homestead Associates in Research, Inc. ( Site 0243) - Homestead
- Floridian Clinical Research, LLC ( Site 0208) - Miami Lakes
Arizona
- The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0 - Chandler
- The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0224) - Peoria
- Arizona Liver Health ( Site 0211) - Tucson
- Del Sol Research Management, LLC ( Site 0209) - Tucson
Georgia
- Southeast Clinical Research Center ( Site 0223) - Dalton
Maryland
- Velocity Clinical Research Rockville ( Site 0245) - Rockville
Nevada
- The Machuca Foundation ( Site 0218) - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2025-06-27 |
| Phase | Phase 2 |
What the finished NCT06482112 record still lists
NCT06482112 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 175-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (29% lower).
The record links to 3 conditions, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which Efinopegdutide is the first listed.
NCT06482112 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06482112 about?
NCT06482112 is a clinical study titled "Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)". This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.
What is the current status of trial NCT06482112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2024-07-29. Estimated completion is 2025-06-27.
What conditions does trial NCT06482112 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease, Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease.
What interventions are being tested in trial NCT06482112?
The interventions under investigation include: Efinopegdutide (DRUG).
Who is sponsoring clinical trial NCT06482112?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06482112 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06482112's enrollment target sits among peer trials
124 16th of 57 higher than 42 of 57 other Non-alcoholic Fatty Liver Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Fatty Liver Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
RECRUITING · Phase 2
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2b Study of GSK4532990 in Adults With NASH
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI